Tarsus Pharmaceuticals (TARS) Other financing activities (2020 - 2026)

Tarsus Pharmaceuticals' Other financing activities history runs 7 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• On a quarterly basis, Other financing activities fell 16.21% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $2.1 million, a 13.42% decrease from a year earlier, with the FY2025 full-year figure at $2.3 million, up 30.19% from the prior year.
• Other financing activities slipped to $1.2 million in Q1 2026 per TARS's latest filing, from $1.2 million in the prior quarter.
• Across five years, Other financing activities topped out at $8.6 million in Q2 2024 and bottomed at -$6.0 million in Q3 2024.
• The 5-year median for Other financing activities is $222000.0 (2022), against an average of $456000.0.
• Across the five-year window, Other financing activities surged 1268.42% in 2022 and sank 1395.48% in 2024, its largest moves.
• Year by year, Other financing activities stood at -$99000.0 in 2022, then soared by 228.28% to $127000.0 in 2023, then sank by 1317.32% to -$1.5 million in 2024, then soared by 179.95% to $1.2 million in 2025, then decreased by 2.59% to $1.2 million in 2026.
• Per Business Quant, the three latest TARS Other financing activities figures stand at $1.2 million (Q1 2026), $1.2 million (Q4 2025), and -$336000.0 (Q2 2025).